New vaccine aims to protect against COVID-19 and future coronavirus threats

NCT ID NCT05548439

First seen May 12, 2026 · Last updated May 15, 2026 · Updated 1 time

Summary

This study tested an experimental vaccine called VBI-2901a in 103 healthy adults aged 18-64 who had already received a COVID-19 vaccine. The vaccine targets three coronaviruses: SARS-CoV-2 (COVID-19), SARS-CoV-1, and MERS-CoV. The goal was to check safety and see if it boosts the immune system against these viruses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID - 19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU de Québec Université Laval

    Québec, Quebec, G1E 7G9, Canada

  • Canadian Center for Vaccinology

    Halifax, Nova Scotia, B3K 6R8, Canada

  • LMC Manna - Bayview CPU

    Toronto, Ontario, M4G 3E8, Canada

  • LMC Manna Toronto

    Toronto, Ontario, M9W 4L6, Canada

  • Manna Research Inc

    Pointe-Claire, Quebec, H9R 4S3, Canada

  • Ottawa Hospital

    Ottawa, Ontario, K1H 8L6, Canada

  • Red Maple Trials

    Ottawa, Ontario, K1H 1E4, Canada

Conditions

Explore the condition pages connected to this study.